J.W. Cole Advisors, Inc. Acadia Pharmaceuticals Inc Transaction History

J.W. Cole Advisors, Inc.

$4.58 Billion
Q2 2025

A detailed history of J.W. Cole Advisors, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 19,981 shares of ACAD stock, worth $453,568. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,981

Previous 23,026 13.22%

Holding current value

$453,568

Previous $382,000 12.57%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$14.1 - $22.95 $42,934 - $69,882	-3,045 Reduced 13.22%	19,981 $430,000
Q1 2025 May 05, 2025	BUY	$16.61 - $20.29 $89,793 - $109,687	5,406 Added 30.68%	23,026 $382,000
Q3 2023 Oct 24, 2023	SELL	$20.84 - $33.47 $5,522 - $8,869	-265 Reduced 1.48%	17,620 $367,000
Q2 2022 Jul 27, 2022	SELL	$13.01 - $27.22 $325 - $680	-25 Reduced 0.14%	17,885 $252,000
Q1 2022 Jun 10, 2022	SELL	$20.94 - $27.5 $17.9 Million - $23.5 Million	-854,205 Reduced 97.95%	17,910 $434,000
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $17.9 Million - $23.5 Million	854,205 Added 4769.43%	872,115 $37,000
Q2 2021 Aug 06, 2021	BUY	$19.4 - $27.42 $484 - $685	25 Added 0.14%	17,910 $437,000
Q1 2021 Apr 28, 2021	SELL	$25.02 - $54.99 $13,610 - $29,914	-544 Reduced 2.95%	17,885 $461,000
Q4 2020 Feb 12, 2021	SELL	$41.04 - $56.79 $31,806 - $44,012	-775 Reduced 4.04%	18,429 $985,000
Q3 2020 Nov 05, 2020	BUY	$36.42 - $57.0 $46,763 - $73,188	1,284 Added 7.17%	19,204 $792,000
Q2 2020 Aug 07, 2020	BUY	$39.26 - $52.73 $703,539 - $944,921	17,920 New	17,920 $869,000
Q1 2020 May 07, 2020	SELL	$31.65 - $46.87 $697,629 - $1.03 Million	-22,042 Closed	0 $0
Q4 2019 Jan 23, 2020	BUY	$36.21 - $51.4 $798,140 - $1.13 Million	22,042 New	22,042 $943,000

Others Institutions Holding ACAD

# of Institutions

350

Shares Held

164M

Call Options Held

811K

Put Options Held

334K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.67B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J.W. Cole Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on J.W. Cole Advisors, Inc. with notifications on news.

Account

J.W. Cole Advisors, Inc. Acadia Pharmaceuticals Inc Transaction History